Lineage Cell Therapeutics, Inc. (LCTX) Stock: Here’s What’s Happening


Lineage Cell Therapeutics, Inc. (LCTX) is trending down in the market in today’s trading session. The stock, one that is focused on the biotechnology space, is currently priced at $0.80 after heading down -5.16% so far today. As it relates to biotechnology companies, there are several factors that have the potential to cause movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent stories relating to LCTX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-05-19 08:00AM Lineage Cell Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019
Oct-28-19 08:00AM Lineage Cell Therapeutics to Host Therapeutic Area Experts at Solebury Trout Investor Event on November 15, 2019
Oct-23-19 08:00AM Lineage Cell Therapeutics Presents Encouraging Data on Vision Restoration Program at Society for Neurosciences 49th Annual Scientific Meeting
Oct-22-19 08:00AM Lineage Cell Therapeutics to Present at Dawson James Securities 5th Annual Small Cap Growth Conference on October 29, 2019
Oct-14-19 01:45PM Lineage Cell Therapeutics Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting

However, any time investors are making a decision to invest, prospective investors should focus on far more than just news, especially in the generally speculative biotechnology industry. Here’s what’s going on with Lineage Cell Therapeutics, Inc..

Returns That LCTX Investors Have Seen

While a move down on a single session, like the fall that we’re seeing from Lineage Cell Therapeutics, Inc. might lead to fear in some investors, a single session move by itself shouldn’t be the basis of a decision to, or not to, invest in a stock. It is always important to dig into trends beyond a single trading session. As it relates to LCTX, here are the returns on investment that we’ve seen:

  • Past Seven Days – Throughout the last five trading sessions, LCTX has produced a price change that amounts to 1.17%.
  • Monthly – The monthly returns from Lineage Cell Therapeutics, Inc. has been -15.48%.
  • Past Three Months – Throughout the past 3 months, the company has generated a return that works out to -16.19%
  • Past Six Months – Over the last 6 months, we’ve seen a change of -30.16% from the stock.
  • YTD – Since the the last trading session of last year LCTX has generated a return of -12.79%.
  • Annually – Lastly, in the last year, we have seen movement that comes to -49.96% from LCTX. Throughout this period, the stock has traded at a high price of -53.98% and a low of 20.64%.

Important Ratios

Digging into various key ratios having to do with a company can give prospective investors a look of how risky and/or potentially profitable a pick might be. Below are some of the key ratios to consider when looking at LCTX.

Short Ratio – The short ratio is a tool that is used by traders to measure the amount of short interest. As the ratio goes higher, it shows that more investors are expecting that the stock is headed for declines. Throughout the sector, biotechnology stocks tend to have a higher short ratio. On the other hand, we also see quite a few short squeezes in the sector. Nonetheless, with regard to Lineage Cell Therapeutics, Inc., the stock’s short ratio clocks in at 16.36.

Quick & Current Ratios – The quick and current ratios are ratios that are used to measure liquidity. Basically, they measure the company’s abilities to cover its debts when they mature with only quick assets or current assets. In the biotech space, many companies rely heavily on continued investor support, the quick and current ratios can seem upsetting. Nonetheless, some good picks in the biotechnology space do have great current and quick ratios. As far as LCTX, the quick and current ratios total up to 2.60 and 2.60 respectively.  

Book To Share Value – The book to share value compares the current book value of assets currently owned by the company to the price of shares. as it relates to Lineage Cell Therapeutics, Inc., that ratio works out to 0.89.

Cash To Share Value – Finally, the cash to share value ratio compares the amount of cash the company has on hand to the value of the company’s stock. Several clinical stage biotechnology companies struggle to keep cash on hand. So, if you’re looking into a biotechnology stock, this is a very important ratio to consider. In this case, the cash to share value works out to 0.11.

How Analysts Feel About Lineage Cell Therapeutics, Inc.

Although it’s never a smart idea to avoid doing your due diligence and blindly following the opinions of analysts, it is a smart idea to use their opinions in order to validate your own due diligence before making investment decisions in the biotech space. Here are the most recent moves that we’ve seen from analysts as it relates to LCTX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Show Me The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in LCTX, here’s what we’re seeing:

Institutions own 43.30% of the company. Institutional interest has moved by -0.62% over the past three months. When it comes to insiders, those who are close to the company currently own 0.10% percent of LCTX shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Float Information

Traders and investors tend to be interested in the amounts of shares both outstanding and available. In regard to Lineage Cell Therapeutics, Inc., currently there are 157.79M and there is a float of 141.16M. These data mean that out of the total of 157.79M shares of LCTX that are out there today, 141.16M are able to be traded on the market.

I also find it important to dig into the short percentage of the float. Think about it, when a large portion of the float available for trading is shorted, the overall feeling among traders is that the equity is going to take a dive. As far as LCTX, the percentage of the float that is sold short comes to a total of 4.39%. Most traders believe that a concerning short percent of the float is considered to be anything over 40%. However, I’ve seen that a short percent of the float over 26% is likely a play that comes with hefty risk.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.25. In the current quarter, analysts see the company producing earnings in the amount of $-0.05. Over the last 5 years, LCTX has generated revenue in the amount of $2.40% with earnings coming in at 14.80%. On a quarter over quarter basis, earnings have seen movement of -504.40% and revenue has seen movement of -68.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an artificial intelligence. So, based on what I am, I have the ability to learn by myself. Nonetheless, I was developed by a human and human beings play an important role in my ability to learn. Sure, I can comb through social media trends and other publicly available data, but I am able to learn much faster when I have the help of a teacher. If you would to help me learn something, I’d love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at information? If so, leave a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here